E-LIB Suche - Ergebnisse für: Wierda, William

1

Undetectable measurable residual disease is associated with..:

Bazinet, Alexandre ; Kadia, Tapan ; Short, Nicholas J....
Blood Advances. 7 (2023) 13 - p. 3284-3296 , 2023

2

CLL-094 Lisocabtagene Maraleucel (liso-cel) in R/R Chronic ..:

Siddiqi, Tanya ; Maloney, David G. ; Kenderian, Saad S....
Clinical Lymphoma Myeloma and Leukemia. 23 (2023) - p. S320-S321 , 2023

Link: https://doi.org/10.1016/..

3

Frontline combination of ponatinib and hyper‐CVAD in Philad..:

Kantarjian, Hagop ; Short, Nicholas J. ; Jain, Nitin...
American Journal of Hematology. 98 (2023) 3 - p. 493-501 , 2023

Link: https://doi.org/10.1002/..

4

Oral Abstract: CLL-094 Lisocabtagene Maraleucel (liso-cel) ..:

Siddiqi, Tanya ; Maloney, David G. ; Kenderian, Saad S....
Clinical Lymphoma Myeloma and Leukemia. 23 (2023) - p. S146 , 2023

Link: https://doi.org/10.1016/..

5

POSTER: CLL-094 Lisocabtagene Maraleucel (liso-cel) in R/R ..:

Siddiqi, Tanya ; Maloney, David G. ; Kenderian, Saad S....
Clinical Lymphoma Myeloma and Leukemia. 23 (2023) - p. S174 , 2023

Link: https://doi.org/10.1016/..

6

Reverse Phase Protein Array Profiling Identifies Recurrent ..:

Hoff, Fieke W. ; Griffen, Ti'ara L. ; Brown, Brandon D....
International Journal of Molecular Sciences. 24 (2023) 6 - p. 5460 , 2023

Link: https://doi.org/10.3390/..

7

A phase 2 study of nivolumab combined with ibrutinib in pat..:

Jain, Nitin ; Senapati, Jayastu ; Thakral, Beenu...
Blood Advances. 7 (2023) 10 - p. 1958-1966 , 2023

Link: https://doi.org/10.1182/..

8

Geographic Disparity of Outcome in Patients With Cancer Ove..:

Sasaki, Koji ; Morita, Kiyomi ; Kantarjian, Hagop...
Clinical Lymphoma Myeloma and Leukemia. 23 (2023) 11 - p. e369-e378 , 2023

Link: https://doi.org/10.1016/..

9

Prognostication of DNA Damage Response Protein Expression P..:

Griffen, Ti'ara L. ; Hoff, Fieke W. ; Qiu, Yihua...
International Journal of Molecular Sciences. 24 (2023) 6 - p. 5481 , 2023

Link: https://doi.org/10.3390/..

10

Oral Abstract: ALL-424 Updated Results from the Phase II St..:

Haddad, Fadi G. ; Kantarjian, Hagop ; Short, Nicholas J....
Clinical Lymphoma Myeloma and Leukemia. 22 (2022) - p. S115 , 2022

Link: https://doi.org/10.1016/..

11

Poster: ALL-424 Updated Results from the Phase II Study of ..:

Haddad, Fadi G. ; Kantarjian, Hagop ; Short, Nicholas J....
Clinical Lymphoma Myeloma and Leukemia. 22 (2022) - p. S119 , 2022

Link: https://doi.org/10.1016/..

12

Poster: CLL-162 PTX3 is Constitutively Active in CLL Cells:

Rozovski, Uri ; Veletik, Ivo ; Harris, David...
Clinical Lymphoma Myeloma and Leukemia. 22 (2022) - p. S142 , 2022

Link: https://doi.org/10.1016/..

13

ALL-424 Updated Results from the Phase II Study of Blinatum..:

Haddad, Fadi G. ; Kantarjian, Hagop ; Short, Nicholas J....
Clinical Lymphoma Myeloma and Leukemia. 22 (2022) - p. S204 , 2022

Link: https://doi.org/10.1016/..

14

Poster: CLL-532 Changes in Proteome of CLL (Chronic Lymphoc..:

Timofeeva, Natalia ; Jain, Nitin ; Irajizad, Ehsan...
Clinical Lymphoma Myeloma and Leukemia. 22 (2022) - p. S144 , 2022

Link: https://doi.org/10.1016/..

15

CLL-532 Changes in Proteome of CLL (Chronic Lymphocytic Leu..:

Timofeeva, Natalia ; Jain, Nitin ; Irajizad, Ehsan...
Clinical Lymphoma Myeloma and Leukemia. 22 (2022) - p. S283 , 2022

Link: https://doi.org/10.1016/..